Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:6:343-63.
doi: 10.2147/OPTH.S29075. Epub 2012 Mar 6.

Insight into 144 patients with ocular vascular events during VEGF antagonist injections

Ahmad M Mansour  1 , Maha Shahin, Peter K Kofoed, Maurizio B Parodi, Michel Shami, Stephen G Schwartz; Collaborative Anti-VEGF Ocular Vascular Complications Group
Affiliations

Insight into 144 patients with ocular vascular events during VEGF antagonist injections

Ahmad M Mansour et al. Clin Ophthalmol. 2012.

Abstract

Aim: To record ocular vascular events following injections of vascular endothelium growth factor (VEGF) antagonists.

Methods: Collaborative multicenter case series (48 cases), literature reviews (32 cases), and reports to the FDA (64 cases) of patients that had vascular occlusions during anti-VEGF therapy were collected and analyzed.

Results: A total of 144 cases of ocular vascular events were identified, with these diagnosed a median of 15 days after anti-VEGF injection. The majority of patients had pre-existing risk factors for cardiovascular events and nine patients had a prior history of glaucoma. Mean visual acuity dropped by 6.4 lines with severe visual loss after injection to NLP (five eyes), LP (six eyes), and HM (two eyes). The overall risk of ocular vascular events following a VEGF antagonist injection was 0.108% in the general population and 2.61% in the diabetic population. Mean retinal arterial constriction after intravitreal bevacizumab in 13 eyes was 21% (standard deviation = 27%), and mean retinal venous constriction was 8% (standard deviation = 30%).

Conclusion: Ocular vascular events are rare during anti-VEGF therapy, but can lead to severe visual loss and may be caused by a number of factors including the vasoconstrictor effect of the drug, a post-injection rise of intraocular pressure, patient stress as a result of the procedure, and the patient's natural history of underlying ocular or systemic diseases. The diabetic population appears to have a tendency towards ocular vascular occlusions.

Keywords: Bevacizumab; ranibizumab; retinal artery occlusion; retinal capillary occlusion; retinal vein occlusion.

PubMed Disclaimer

References

    1. Liu MH, Jin H, Floten HS, Ren Z, Yim AP, He GW. Vascular endothelial growth factor-mediated, endothelium-dependent relaxation in human internal mammary artery. Ann Thorac Surg. 2002;73(3):819–824. - PubMed
    1. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. Primary intravitreal bevacizumab (avastin) for diabetic macular edema. Results from the Pan-American Collaborative Study Group at 6-month follow-up. Ophthalmology. 2007;114(4):743–750. - PubMed
    1. Soliman W, Vinten M, Sander B, et al. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema. Acta Ophthalmol. 2008;86(4):365–371. - PubMed
    1. Michaelides M, Fraser-Bell S, Hamilton R, et al. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): Report 1. Retina. 2010;30(5):781–786. - PubMed
    1. Kook D, Wolf A, Kreutzer T, et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina. 2008;28(8):1053–1060. - PubMed